Proton pump inhibitors associated with hearing loss in people with type 2 diabetes

ObjectiveThe association between the regular use of proton pump inhibitors (PPIs) and the risk of type 2 diabetes remains unclear, although a recent randomised controlled trial showed a trend towards increased risk. This study was undertaken to evaluate the regular use of PPIs and risk of type 2 diabetes.MethodThis is a prospective analysis of 204 689 participants free of diabetes in the Nurses' Health Study (NHS), NHS II and Health Professionals Follow-up Study (HPFS). Type 2 diabetes was confirmed using American Diabetes Association (ADA) diagnostic criteria. We evaluated hazard ratios (HRs) adjusting for demographic factors, lifestyle habits, the presence of comorbidities, use of other medications and clinical indications.ResultsWe documented 10 105 incident cases of diabetes over 2 127 471 person-years of follow-up. Regular PPI users had a 24% higher risk of diabetes than non-users (HR 1.24, 95% CI 1.17 to 1.31). The risk of diabetes increased with duration of PPI use. Fully adjusted HRs were 1.05 (95% CI 0.93 to 1.19) for participants who used PPIs for >0–2 years and 1.26 (95% CI 1.18 to 1.35) for participants who used PPIs for >2 years compared with non-users.ConclusionsRegular use of PPIs was associated with a higher risk of type 2 diabetes and the risk increased with longer duration of use. Physicians should therefore exercise caution when prescribing PPIs, particularly for long-term use.

Download Full-text

The Effect of Proton Pump Inhibitors on Glycemic Control in Patients with Type 2 Diabetes

Metabolic Syndrome and Related Disorders ◽

10.1089/met.2018.0138 ◽

2019 ◽

Vol 17 (4) ◽

pp. 192-196 ◽

Cited By ~ 3

Author(s):

Kelly Villegas ◽

Joy L. Meier ◽

Maureen Long ◽

Julio Lopez ◽

Arthur Swislocki

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Proton Pump Inhibitors ◽

Proton Pump

Download Full-text

Effect of Proton-Pump Inhibitors on Glucose and Insulin Metabolism on Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Current Pharmaceutical Design ◽

10.2174/1381612826666200523170718 ◽

2020 ◽

Vol 26 (32) ◽

pp. 4007-4013

Author(s):

Adriana Sánchez-García ◽

Mario Simental-Mendía ◽

Luis E. Simental-Mendía

Keyword(s):

Systematic Review ◽

Type 2 Diabetes ◽

Randomized Controlled Trials ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Meta Analysis ◽

Controlled Trials ◽

Insulin Metabolism ◽

Randomized Controlled

Background: Some studies have revealed an improvement in glucose metabolism after proton-pump inhibitors (PPI) therapy; however, this evidence is inconclusive and limited. Objective: The study aimed to examine the effect of PPI on glucose and insulin metabolism in patients with type 2 diabetes through a systematic review and meta-analysis. Methods: Only randomized controlled trials evaluating the impact of PPI on glucose or insulin concentrations in type 2 diabetes were searched in PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases. A meta-analysis was conducted using a random-effects model and generic inverse variance method. Sensitivity analysis was performed using the leave-one-out method. Results: Meta-analysis revealed no significant effect of PPI intervention on fasting glucose (mean difference [MD] -11.42 [95% CI, -29.68 to 6.83], I2 = 80%, p = 0.22), fasting insulin (MD 1.51 [95% CI, -0.36 to 3.37], I2 = 32%, p = 0.11), HOMA-IR (MD -0.16 [-0.98 to 0.65], I2 = 0%, p = 0.70), HOMA-β (MD 19.97 [-21.59 to 61.52], I2 = 71%, p = 0.35), and HbA1c concentrations (MD -0.34 [-0.99 to 0.31], I2 = 89%, p = 0.30). Conclusion: The treatment with PPI, in the short term, had no significant effects on glucose and insulin metabolism in patients with type 2 diabetes.

Download Full-text